Journal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 22, Issue 11, Pages 847-852Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2022.07.011
Keywords
Myeloma; Daratumumab; immunotherapy; Transplant; Minimal residual disease
Categories
Ask authors/readers for more resources
The study investigated the combination of Daratumumab with cyclophosphamide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients. The results showed high rates of complete response and a favorable progression-free survival rate, indicating the effectiveness of the treatment regimen.
The phase 1b 16-BCNI-001/CTRIAL-IE 16-02 CyBorD-DARA trial investigated the combination of Daratumumab with cyclophosphamide, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM), followed by autologous stem cell transplantation and Daratumumab maintenance. CR/sCR rates were 50% after transplant and 62.5% at end of treatment. Progression-free survival rate at end of maintenance was 81.3% and estimated 2-year overall survival was 88.9%. 37.5% of patients demonstrated sustained MRD negativity to a level of 10(-5). The phase 1b 16-BCNI-001/CTRIAL-IE 16-02 CyBorD-DARA trial investigated the combination of Daratumumab with cyclophosphamide, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM), followed by autologous stem cell transplantation and Daratumumab maintenance. CR/sCR rates were 50% after transplant and 62.5% at end of treatment. The overall percentage of patients achieving complete response or better was 77.8%. Progression-free survival rate at end of maintenance was 81.3% and estimated 2-year overall survival was 88.9%. 37.5% of patients demonstrated sustained MRD negativity to a level of 10(-5) from transplant to analysis at EOT. In this phase 1b study, we have shown CyBorD-DARA to be an effective and well-tolerated immunomodulatory agent-free regiment in transplant-eligible NDMM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available